An open-label, randomized phase II study comparing first-line treatment with dovitinib (TKI258) versus sorafenib in patients with advanced hepatocellular carcinoma.
Ann-Lii Cheng
Honoraria - Novartis
Ho Yeong Lim
No relevant relationships to disclose
Ronnie Tung Ping Poon
Consultant or Advisory Role - Novartis
Sumitra Throngprasert
Consultant or Advisory Role - Lilly (U); Novartis (U); Pfizer (U)
Honoraria - AstraZeneca; Roche
Research Funding - Novartis; Pfizer; Roche
Cathy Reddick
Employment or Leadership Position - Novartis
Stock Ownership - Novartis (B)
Yong Zhang
Employment or Leadership Position - Novartis
Michael Shi
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Eugene Tan
Employment or Leadership Position - Novartis
Yongyu Wang
Employment or Leadership Position - Novartis